Cancer Genetics, Inc. (CGIX) News

Cancer Genetics, Inc. (CGIX): $4.61

-0.11 (-2.33%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CGIX News Items

CGIX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CGIX News Highlights

  • CGIX's 30 day story count now stands at 4.
  • Over the past 19 days, the trend for CGIX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • BIO, DE and VIVO are the most mentioned tickers in articles about CGIX.

Latest CGIX News From Around the Web

Below are the latest news stories about Cancer Genetics Inc that investors may wish to consider to help them evaluate CGIX as an investment opportunity.

Cancer Genetics and StemoniX Announce Merger Closing

Cancer Genetics, Inc. Renamed to Vyant Bio, Inc. Vyant Bio, Inc. will begin trading on Nasdaq under the symbol VYNT CHERRY HILL, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company” or “CGI”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, and StemoniX, Inc. (“StemoniX”), a company empowering the discovery of new medicines through the convergence of novel human biology and software technologies, today announced their recently approved transaction has closed, and in connection with the merger, Cancer Genetics, Inc. was renamed Vyant Bio, Inc. (“Vyant Bio”) effective March 30, 2021. StemoniX will operate as a wholly-owned subsidiary of the Company. Vyant Bio will be traded on the Nasdaq under the symbol VYNT beginning on March 31, 2021. The ...

Yahoo | March 31, 2021

Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX

Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline of the combined company RUTHERFORD, N.J., March 25, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced the results of its March 24, 2021 shareholder meeting to approve the upcoming merger with StemoniX, Inc. ("StemoniX"). At a Special Meeting of Stockholders, CGI’s stockholders, upon the unanimous recommendation of the board of directors of CGI: (a) voted in favor of the issuance of shares of Common Stock, warrants and options pursuant to the Agreement and Plan of Merger and Reorganization, dated a...

Yahoo | March 25, 2021

Cancer Genetics (CGIX) Investor Presentation - Slideshow

The following slide deck was published by Cancer Genetics, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | March 12, 2021

Cancer Genetics to Present at the Annual 33rd ROTH Conference

RUTHERFORD, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief Executive Officer, will present at the Annual 33rd ROTH Conference. The event is being held virtually from March 15-17, 2021. Conference Date: March 15-17, 2021 (Monday-Wednesday)1x1 Meetings9:00 am-5:55 pm ET (Monday-Wednesday)Registration: Click Here Mr. Roberts will highlight the Company's recent transformational business strategy, including the Company’s proposed merger with StemoniX, Inc., and elaborate on the broader going- forward corporate vision. If you are an investor and would like to attend the Company’s presentation, please click on the following link (https://www.meetmax.com...

Yahoo | March 12, 2021

Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference

RUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief Executive Officer, will present at H.C. Wainwright’s Global Life Sciences Conference. The event is being held virtually from March 9-10, 2021. Conference Date: March 9-10, 2021 (Tuesday-Wednesday)On-Demand Starts: 7:00 am ET - Tuesday, March 9, 2021On-Demand Ends7:00 pm ET- Wednesday, March 10, 2021 Registration: https://hcwevents.com/globalconference/#toggle-id-1 Mr. Roberts will highlight the Company's recent transformational business strategy, including the Company’s proposed merger with StemoniX, Inc., and elaborate on the broader going- forward corporate vision. If you are an institu...

Yahoo | March 4, 2021

Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules

RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced the closing of its previously announced registered direct offering with several healthcare-focused institutional investors of 2,777,778 shares of its common stock at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the offering totaled approximately $17.5 million, before deducting placement agent fees and offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The Company currently intends to use the net proceeds from the offering for general corporate purposes, including workin...

Yahoo | February 16, 2021

The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X Genomics Inc (NASDAQ: TXG ) 9 Meters Biopharma Inc (NASDAQ: NMTR ) Abbott Laboratories (NYSE: ABT ) Acasti Pharma Inc (NASDAQ: ACST ) (reacted to its quarterly results) Advaxis, Inc. (NASDAQ: ADXS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Alimera Sciences Inc (NASDAQ: ALIM ) Alkermes Plc (NASDAQ: ALKS ) Allakos Inc (NASDAQ: ALLK ) Anchiano Therapeutics Ltd – ADR (NASDAQ: ANCN AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Apyx Medical Corp (NASDAQ: APYX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) AtriCure Inc. (NASD...

Benzinga | February 11, 2021

42 Stocks Moving in Wednesday's Pre-Market Session

Gainers Cancer Genetics, Inc. (NASDAQ: CGIX) shares rose 200.7% to $17.35 in pre-market trading after climbing over 20% on Tuesday. Cancer Genetics, last …

Benzinga | February 10, 2021

CGIX Stock: Why Cancer Genetics Shares Are Rocketing Higher Today

CGIX stock is on the move Wednesday ahead of a shareholder vote on its merger with StemoniX. Here's what you should know now.

InvestorPlace | February 10, 2021

EFFECT - CANCER GENETICS, INC (0001349929) (Filer) - Stocks News Feed

Accepted 2021-02-09 00:15:33 Documents Thank you for supporting Stocks News Feed. As an Amazon affiliate, we earn from qualifying purchases. 1 Effectiveness Date 2021-02-08 Registration Form S-3 Document Format Files Mailing Address 201 ROUTE 17 NORTH 2ND FLOOR RUTHERFORD NJ 07070 Business Address 201 ROUTE 17 NORTH 2ND FLOOR RUTHERFORD NJ 07070 201.528.9200 CANCER GENETICS,… Read More »EFFECT – CANCER GENETICS, INC (0001349929) (Filer)

Stocks News Feed | February 8, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.628 seconds.